# Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

> **NCT02911142** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 17 (actual)

## Conditions studied

- Primary Effusion Lymphoma
- B-Cell Neoplasm

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Rituximab
- **DRUG:** Prednisone
- **DRUG:** Etoposide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DIAGNOSTIC_TEST:** CT of neck, chest, abdomen and pelvis
- **DIAGNOSTIC_TEST:** 18FDG-PET scan
- **DIAGNOSTIC_TEST:** MRI Brain
- **PROCEDURE:** Bone marrow biopsy
- **DIAGNOSTIC_TEST:** EKG
- **DIAGNOSTIC_TEST:** Echocardiogram
- **DIAGNOSTIC_TEST:** Ultrasound
- **DIAGNOSTIC_TEST:** Bronchoscopy
- **DIAGNOSTIC_TEST:** Endoscopy
- **DIAGNOSTIC_TEST:** CXR: PA/lat/decub

## Key facts

- **NCT ID:** NCT02911142
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-03
- **Primary completion:** 2024-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02911142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02911142, "Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02911142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*